|
|
Volumn 296, Issue 5577, 2002, Pages 2320-2324
|
|
Confronting the limits of success
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DISEASES;
DRUG PRODUCTS;
CONFRONTATION;
BIOMEDICAL ENGINEERING;
1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE;
6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE;
ABACAVIR;
AMPRENAVIR;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ATAZANAVIR;
CD4 ANTIGEN;
DELAVIRDINE;
DIDANOSINE;
EFAVIRENZ;
EMTRICITABINE;
ENFUVIRTIDE;
ETRAVIRINE;
INDINAVIR;
LAMIVUDINE;
LOPINAVIR;
N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE;
NELFINAVIR;
NEVIRAPINE;
PROTEINASE;
RITONAVIR;
RNA DIRECTED DNA POLYMERASE;
SAQUINAVIR;
STAVUDINE;
T 1249;
TENOFOVIR;
TIPRANAVIR;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ZALCITABINE;
ZIDOVUDINE;
DRUG DEVELOPMENT;
HUMAN IMMUNODEFICIENCY VIRUS;
ANEMIA;
ANTIVIRAL ACTIVITY;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG SAFETY;
HEALTH CARE POLICY;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LIPODYSTROPHY;
NAUSEA;
OUTCOMES RESEARCH;
PRIORITY JOURNAL;
REVIEW;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ANTIBIOTIC RESISTANCE;
ARTICLE;
CD4 LYMPHOCYTE COUNT;
DRUG ADMINISTRATION;
DRUG EFFECT;
GENETICS;
HUMAN IMMUNODEFICIENCY VIRUS;
IMMUNOLOGY;
MUTATION;
PHYSIOLOGY;
PRACTICE GUIDELINE;
TIME;
TREATMENT OUTCOME;
VIROLOGY;
VIRUS LOAD;
HUMAN IMMUNODEFICIENCY VIRUS;
ACQUIRED IMMUNODEFICIENCY SYNDROME;
ANTI-HIV AGENTS;
ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;
CD4 LYMPHOCYTE COUNT;
CLINICAL TRIALS;
DRUG ADMINISTRATION SCHEDULE;
DRUG RESISTANCE, VIRAL;
HIV;
HIV INFECTIONS;
HUMANS;
MUTATION;
PRACTICE GUIDELINES;
TIME FACTORS;
TREATMENT OUTCOME;
VIRAL LOAD;
|
|
EID: 0037188848
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.296.5577.2320 Document Type: Review |
|
Times cited : (58)
|
|
References (0)
|